Axogen, Inc. — Director's Dealing 2023

Sep 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Axogen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2023-09-01

Reporting Person: Freitag Gregory Gene (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-01	Stock Option (right to purchase)	$6.3	A	20436	Acquired	2033-09-01	Common Stock (20436.0)	Direct
2023-09-01	Restricted Stock Units	$	A	11904	Acquired		Common Stock (11904.0)	Direct

Footnotes

F1: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.